

5

NEISSERIA MENINGITIDIS SEROGROUP B
GLYCOCONJUGATES AND METHODS OF USING THE SAME

10

Abstract of the Invention

15

20

25

30

35

The present invention pertains generally to novel *Neisseria meningitidis* serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a *Neisseria meningitidis* serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent *Neisseria meningitidis* serogroup B or *E. coli* K1 disease in a mammalian subject.